Viewpoint: Professional integrity in industry-sponsored clinical trials

Franklin G. Miller, Howard Brody

Research output: Contribution to journalReview articlepeer-review

24 Scopus citations


Evidence-based medicine (EBM) relies on accurate data derived from well-designed, clinically relevant randomized controlled trials (RCTs). Most randomized trials, however, are conducted by industry sponsors aiming at licensing and marketing drugs, which may weaken the usefulness of the findings to EBM. Disturbing evidence has emerged of widespread biases in industry-sponsored trials, including publication bias, selective reporting of findings, and distorted interpretation of results. These practices compromise the professional integrity of physician-investigators who contribute to them. In turn, the well-being of patients participating in RCTs may be jeopardized, and the evidence base upon which EBM is practiced may be corrupted. Regulatory reform alone will be inadequate to resolve these problems; attention must also be paid to physicians' professionalism. The authors recommend a change in the culture of academic medicine whereby physician-investigators who maintain professional integrity are rewarded or recognized. Educational interventions promoting integrity in clinical research may be one part of affecting such change.

Original languageEnglish (US)
Pages (from-to)899-904
Number of pages6
JournalAcademic Medicine
Issue number10
StatePublished - Oct 2005
Externally publishedYes

ASJC Scopus subject areas

  • Education


Dive into the research topics of 'Viewpoint: Professional integrity in industry-sponsored clinical trials'. Together they form a unique fingerprint.

Cite this